Improved HCP quantitation by minimizing antibody cross-reactivity to target proteins

BioProcess International

Volumn 8, Issue 1, 2010, Pages 18-24

  Wang, Xing ^a   Schomogy, Thomas ^a   Wells, Kristine ^a   Mozier, Ned M ^a  

^a PFIZER INC   (United States)

Author keywords

Cross reactivity; ELISA; Host cell proteins; Risk management; Western blotting

Indexed keywords

ANTIBODY; CELL PROTEIN; DNA; MONOCLONAL ANTIBODY;

ARTICLE; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; HOST CELL; MAMMAL CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION;

EID: 77953469350     PISSN: 15426319     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (11)

1. Hoffman K. Strategies for Host Cell Protein Analysis. BioPharm 13(6) 2000: 38-45.
2. Wang X, Hunter AK, Mozier NM. Host Cell Proteins in Biologics Development: Identification, Quantitation and Risk Assessment. Biotechnol. Bioeng. 103(3) 2009: 446-458.
3. Hayduk EJ, Choe LH, Lee KH. A Two-Dimensional Electrophoresis Map of Chinese Hamster Ovary Cell Proteins Based on Fluorescence Staining. Electrophor. 25(25) 2004: 2545-2556.
4. Nishihara JC, Champion KM. Quantitative Evaluation of Proteins in One-and Two-Dimensional Polyacrylamide Gels Using a Fluorescence Stain. Electrophor. 23(14) 2002: 2203-2215.
5. Smales CM, et al. Comparative Proteomic Analysis of GS-NS0 Murine Myeloma Cell Line with Varying Recombinant Monoclonal Antibody Production Rate. Biotechnol. Bioeng. 88(4) 2004: 474-488.
6. ICH Q2 (R1). Validation of Analytical Procedures: Text and Methodology. Fed. Reg. 62 (96) 1997: 27463-27467.
7. Dyk DDV, et al. Identification of Cellular Changes Associated with Increased Production of Human Growth Hormone in a Recombinant Chinese Hamster Ovary Cell Line. Proteomics 3, 2003: 147-156.
8. Krawitz DC, et al. Proteomic Studies Support the Use of Multi-Product Immunoassays to Monitor Host Cell Protein Impurities. Proteomics 6, 2006: 94-110.
9. Champion K, et al. Defining Your Product Profile and Maintaining Control Over It, Part 2. BioProcess Int. 3(8) 2005: 52-57.
10. CPMP/BWP/382/97. CPMP Position Statement on DNA and Host Cell Proteins (HCP) Impurities: Routine Testing Versus Validation Studies. EMEA: London, UK, 10 June 1997; www.emea.europa.eu/pdfs/human/press/pos/038297en.pdf.
11. CBER. Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use. US Food and Drug Administration: Rockville, MD, 28 February 1997; www.fda.gov/downloads/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/OtherRecommendationsforManufacturers/ UCM153182.pdf.